Clinical Trial

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of small molecule kinase inhibitor or well-differentiated (W-D) G3 GEP-NET who failed to one line of small molecule kinase inhibitor or chemotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-09-09; most recent amendment 2026-04-06.
Status change: Not Yet Recruiting → Recruiting 2023-04-05
Trial Details
NCT Number NCT05048901
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Tri-Service General Hospital (TSGH), Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital
Conditions Neuroendocrine Tumors,Gastroenteropancreatic
Enrollment 49 participants
Start Date 2021-09-17
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-09